Mehmet Gunduz – författare

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single VolumeThe book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer DiagnosisPresents noninvasive early molecular markers in urological cancersDescribes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myelomaProvides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanomaThis text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.

Early detection is critical for any given cancer. With the advent of the latest omics technologies, molecular markers in combination with conventional diagnostic and screening methods are emerging as next-generation early diagnostic and prognostic strategies that can allow early-stage diagnosis, resulting in more effective treatment and patient care and, in turn, an increased rate of survival. A ready-made resource, Noninvasive Molecular Markers in Gynecologic Cancers not only provides information on noninvasive molecular diagnostic biomarkers, it includes coverage of the epidemiology, clinical features, conventional diagnosis, treatment, and prognosis for these cancers.With contributions from leading international experts, the book presents a compact but comprehensive overview of gynecologic cancer. Each of the five main gynecologic cancers—ovarian, cervical, uterine, vaginal, and vulvar—have unique signs and symptoms, risk factors, and molecular profile, and therefore requires different prevention strategies. This book describes the different features of each gynecologic cancer in separate chapters covering general information, epidemiology, clinical features, and biomarkers. The book also covers breast cancer and, although rare, fallopian tube cancer, to make it a complete resource. In cancer treatment, non-invasive diagnosis can avoid complications of biopsy and other unfavorable impacts on patients’ health. DNA, methylation, SNPs, miRNA, mRNA, protein, autoantibodies, metabolite, and omics-based markers from remote media such as blood, plasma, and urine are emerging as noninvasive molecular markers with high specificity and sensitivity towards many cancers. This book classifies the available molecular tumor markers according to their principal characteristics and relative methodologies. It covers markers that not only provide early detection and better treatment options, but are emerging as next-generation personalized diagnostics and targets or therapeutics for personalized cancer treatment.

Early detection is critical for any given cancer. With the advent of the latest omics technologies, molecular markers in combination with conventional diagnostic and screening methods are emerging as next-generation early diagnostic and prognostic strategies that can allow early-stage diagnosis, resulting in more effective treatment and patient care and, in turn, an increased rate of survival. A ready-made resource, Noninvasive Molecular Markers in Gynecologic Cancers not only provides information on noninvasive molecular diagnostic biomarkers, it includes coverage of the epidemiology, clinical features, conventional diagnosis, treatment, and prognosis for these cancers.With contributions from leading international experts, the book presents a compact but comprehensive overview of gynecologic cancer. Each of the five main gynecologic cancers—ovarian, cervical, uterine, vaginal, and vulvar—have unique signs and symptoms, risk factors, and molecular profile, and therefore requires different prevention strategies. This book describes the different features of each gynecologic cancer in separate chapters covering general information, epidemiology, clinical features, and biomarkers. The book also covers breast cancer and, although rare, fallopian tube cancer, to make it a complete resource. In cancer treatment, non-invasive diagnosis can avoid complications of biopsy and other unfavorable impacts on patients’ health. DNA, methylation, SNPs, miRNA, mRNA, protein, autoantibodies, metabolite, and omics-based markers from remote media such as blood, plasma, and urine are emerging as noninvasive molecular markers with high specificity and sensitivity towards many cancers. This book classifies the available molecular tumor markers according to their principal characteristics and relative methodologies. It covers markers that not only provide early detection and better treatment options, but are emerging as next-generation personalized diagnostics and targets or therapeutics for personalized cancer treatment.

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single VolumeThe book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer DiagnosisPresents noninvasive early molecular markers in urological cancersDescribes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myelomaProvides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanomaThis text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.